The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes
The gastrointestinal tract is inhabited by trillions of commensal microorganisms that constitute the gut microbiota. As a main metabolic organ, the gut microbiota has co-evolved in a symbiotic relationship with its host, contributing to physiological homeostasis. Recent advances have provided mechan...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1096551/full |
| _version_ | 1797952103398768640 |
|---|---|
| author | Man Wang Lei Zhang Wenguang Chang Yuan Zhang |
| author_facet | Man Wang Lei Zhang Wenguang Chang Yuan Zhang |
| author_sort | Man Wang |
| collection | DOAJ |
| description | The gastrointestinal tract is inhabited by trillions of commensal microorganisms that constitute the gut microbiota. As a main metabolic organ, the gut microbiota has co-evolved in a symbiotic relationship with its host, contributing to physiological homeostasis. Recent advances have provided mechanistic insights into the dual role of the gut microbiota in cancer pathogenesis. Particularly, compelling evidence indicates that the gut microbiota exerts regulatory effects on the host immune system to fight against cancer development. Some microbiota-derived metabolites have been suggested as potential activators of antitumor immunity. On the contrary, the disequilibrium of intestinal microbial communities, a condition termed dysbiosis, can induce cancer development. The altered gut microbiota reprograms the hostile tumor microenvironment (TME), thus allowing cancer cells to avoid immunosurvelliance. Furthermore, the gut microbiota has been associated with the effects and complications of cancer therapy given its prominent immunoregulatory properties. Therapeutic measures that aim to manipulate the interplay between the gut microbiota and tumor immunity may bring new breakthroughs in cancer treatment. Herein, we provide a comprehensive update on the evidence for the implication of the gut microbiota in immune-oncology and discuss the fundamental mechanisms underlying the influence of intestinal microbial communities on systemic cancer therapy, in order to provide important clues toward improving treatment outcomes in cancer patients. |
| first_indexed | 2024-04-10T22:41:03Z |
| format | Article |
| id | doaj.art-cdd56c61279c45cb80a7674f9d3817ac |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T22:41:03Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-cdd56c61279c45cb80a7674f9d3817ac2023-01-16T05:16:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011310.3389/fimmu.2022.10965511096551The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomesMan WangLei ZhangWenguang ChangYuan ZhangThe gastrointestinal tract is inhabited by trillions of commensal microorganisms that constitute the gut microbiota. As a main metabolic organ, the gut microbiota has co-evolved in a symbiotic relationship with its host, contributing to physiological homeostasis. Recent advances have provided mechanistic insights into the dual role of the gut microbiota in cancer pathogenesis. Particularly, compelling evidence indicates that the gut microbiota exerts regulatory effects on the host immune system to fight against cancer development. Some microbiota-derived metabolites have been suggested as potential activators of antitumor immunity. On the contrary, the disequilibrium of intestinal microbial communities, a condition termed dysbiosis, can induce cancer development. The altered gut microbiota reprograms the hostile tumor microenvironment (TME), thus allowing cancer cells to avoid immunosurvelliance. Furthermore, the gut microbiota has been associated with the effects and complications of cancer therapy given its prominent immunoregulatory properties. Therapeutic measures that aim to manipulate the interplay between the gut microbiota and tumor immunity may bring new breakthroughs in cancer treatment. Herein, we provide a comprehensive update on the evidence for the implication of the gut microbiota in immune-oncology and discuss the fundamental mechanisms underlying the influence of intestinal microbial communities on systemic cancer therapy, in order to provide important clues toward improving treatment outcomes in cancer patients.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1096551/fullgut microbiotacancer pathogenesismicrobiota-derived metabolitesdysbiosistumor immunitytreatment outcomes |
| spellingShingle | Man Wang Lei Zhang Wenguang Chang Yuan Zhang The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes Frontiers in Immunology gut microbiota cancer pathogenesis microbiota-derived metabolites dysbiosis tumor immunity treatment outcomes |
| title | The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes |
| title_full | The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes |
| title_fullStr | The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes |
| title_full_unstemmed | The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes |
| title_short | The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes |
| title_sort | crosstalk between the gut microbiota and tumor immunity implications for cancer progression and treatment outcomes |
| topic | gut microbiota cancer pathogenesis microbiota-derived metabolites dysbiosis tumor immunity treatment outcomes |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1096551/full |
| work_keys_str_mv | AT manwang thecrosstalkbetweenthegutmicrobiotaandtumorimmunityimplicationsforcancerprogressionandtreatmentoutcomes AT leizhang thecrosstalkbetweenthegutmicrobiotaandtumorimmunityimplicationsforcancerprogressionandtreatmentoutcomes AT wenguangchang thecrosstalkbetweenthegutmicrobiotaandtumorimmunityimplicationsforcancerprogressionandtreatmentoutcomes AT yuanzhang thecrosstalkbetweenthegutmicrobiotaandtumorimmunityimplicationsforcancerprogressionandtreatmentoutcomes AT manwang crosstalkbetweenthegutmicrobiotaandtumorimmunityimplicationsforcancerprogressionandtreatmentoutcomes AT leizhang crosstalkbetweenthegutmicrobiotaandtumorimmunityimplicationsforcancerprogressionandtreatmentoutcomes AT wenguangchang crosstalkbetweenthegutmicrobiotaandtumorimmunityimplicationsforcancerprogressionandtreatmentoutcomes AT yuanzhang crosstalkbetweenthegutmicrobiotaandtumorimmunityimplicationsforcancerprogressionandtreatmentoutcomes |